Severe Genotype, Pancreatic Insufficiency and Low Dose of Pancreatic Enzymes Associate with Abnormal Serum Sterol Profile in Cystic Fibrosis

• Main Authors: Sławomira Drzymała-Czyż, Patrycja Krzyżanowska-Jankowska, Krzysztof Dziedzic, Aleksandra Lisowska, Szymon Kurek, Joanna Goździk-Spychalska, Victoria Kononets, Dagmara Woźniak, Edyta Mądry, Jarosław Walkowiak
• Format: Article
• Language: English
• Published: MDPI AG 2021-02-01
• Series: Biomolecules
• Subjects: campesterol; β-sitosterol; stigmasterol; cholesterol; lathosterol
• Online Access: https://www.mdpi.com/2218-273X/11/2/313

Background: Several factors could lead to lipid disturbances observed in cystic fibrosis (CF). This study aimed to assess sterol homeostasis in CF and define potential exogenous and endogenous determinants of lipid dysregulation. Methods: The study involved 55 CF patients and 45 healthy subjects (HS). Sterol concentrations (μg/dL) were measured by gas chromatography/mass spectrometry. CF was characterised by lung function, pancreatic status, liver disease and diabetes coexistence, <i>Pseudomonas aeruginosa</i> colonisation and BMI. <i>CFTR</i> genotypes were classified as severe or other. Results: Campesterol and β-sitosterol concentrations were lower (<i>p</i> = 0.0028 and <i>p</i> < 0.0001, respectively) and lathosterol levels (reflecting endogenous cholesterol biosynthesis) were higher (<i>p</i> = 0.0016) in CF patients than in HS. Campesterol and β-sitosterol concentrations were lower in patients with a severe <i>CFTR</i> genotype, pancreatic insufficiency and lower pancreatic enzyme dose (lipase units/gram of fat). In multiple regression analyses, β-sitosterol and campesterol concentrations were predicted by genotype and pancreatic insufficiency, whereas cholesterol and its fractions were predicted by phytosterol concentrations, age, dose of pancreatic enzymes, nutritional status and genotype. Conclusions: Independent determinants of lipid status suggest that malabsorption and pancreatic enzyme supplementation play a significant role in sterol abnormalities. The measurement of campesterol and β-sitosterol concentrations in CF patients may serve for the assessment of the effectiveness of pancreatic enzyme replacement therapy and/or compliance, but further research is required.